Actively Recruiting
Evaluating Aztreonam-Avibactam for Safety and Pharmacokinetics in Hospitalized Newborns and Infants With Gram-Negative Bacterial Infections
Led by Pfizer · Updated on 2026-10-15
48
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacokinetics of a combination antibiotic medicine called aztreonam-avibactam ATM-AVI for treating infections caused by gram-negative bacteria in newborns and infants up to 9 months old who are hospitalized. The study is a Phase 2a, open-label, non-randomized trial conducted in multiple centers. It includes preterm and full-term infants divided into four age cohorts, focusing on how the medicine behaves and its effects in this young population. The study has two parts Part A and Part B. In Part A, participants receive a single 3-hour intravenous infusion of ATM-AVI to study the safety and pharmacokinetics of one dose. Part B involves multiple 3-hour intravenous infusions every 6 to 8 hours for 3 to 14 days as treatment for suspected or confirmed gram-negative bacterial infections. Participants with complicated intra-abdominal infections may also receive intravenous metronidazole, and additional antibiotics may be given for gram-positive bacteria if needed. Some participants may switch to oral antibiotics after at least 72 hours of intravenous treatment if clinically appropriate. Participants will undergo blood level assessments of ATM-AVI during and after dosing to monitor pharmacokinetics. Safety will be observed for 48 hours after the single infusion in Part A, with a follow-up safety call 4 to 5 weeks later. In Part B, clinical response will be evaluated at the end of intravenous and oral treatment and again 7 to 14 days after treatment ends. An independent committee will monitor safety throughout. Total participation lasts about 5 weeks for Part A and up to 7 weeks for Part B, including follow-up assessments.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here